Jounce Therapeutics (Jounce Therapeutics) Pre-Tax Income : $-50.78 Mil (TTM As of Dec. 2022)

View and export this data going back to 2017. Start your Free Trial

What is Jounce Therapeutics Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Jounce Therapeutics's pretax income for the three months ended in Dec. 2022 was $51.08 Mil. Its pretax income for the trailing twelve months (TTM) ended in Dec. 2022 was $-50.78 Mil. Jounce Therapeutics's pretax margin was 62.29%.

During the past 9 years, Jounce Therapeutics's highest Pretax Margin was 38.46%. The lowest was -337.67%. And the median was -41.92%.

Jounce Therapeutics Pre-Tax Income Historical Data

The historical data trend for Jounce Therapeutics's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jounce Therapeutics Pre-Tax Income Chart

Jounce Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Pre-Tax Income

Get a 7-Day Free Trial

-27.33

56.87

-43.83

-90.86

-50.78

Jounce Therapeutics Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
Pre-Tax Income	Get a 7-Day Free Trial															-30.23	-37.37	-33.50	-30.99	51.08

Competitive Comparison of Jounce Therapeutics's Pre-Tax Income

For the Biotechnology subindustry, Jounce Therapeutics's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Jounce Therapeutics's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jounce Therapeutics's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Jounce Therapeutics's Pre-Tax Income falls into.

Jounce Therapeutics Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Jounce Therapeutics's Pretax Income for the fiscal year that ended in Dec. 2022 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-52.242	+	1.458	+	0	+	0	+	0
	=	-50.78

Jounce Therapeutics's Pretax Income for the quarter that ended in Dec. 2022 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	50.339	+	0.737	+	0	+	0	+	0
	=	51.08

Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-50.78 Mil.

Jounce Therapeutics (NAS:JNCE) Pre-Tax Income Explanation

Jounce Therapeutics's Pretax Margin for the quarter that ended in Dec. 2022 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	51.076	/	82
	=	62.29%

During the past 9 years, Jounce Therapeutics's highest Pretax Margin was 38.46%. The lowest was -337.67%. And the median was -41.92%.

Jounce Therapeutics Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Jounce Therapeutics's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Jounce Therapeutics (Jounce Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jounce Therapeutics Inc (NAS:JNCE) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

780 Memorial Drive, Cambridge, MA, USA, 02139

Website

https://www.jouncetx.com

Jounce Therapeutics Inc is a clinical stage immunotherapy company. It is engaged in developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. The company primarily operates only in the United States. The company has developed a suite of integrated technologies that comprise a Translational Science Platform, enabling it to comprehensively interrogate the cellular and molecular composition of tumors.

Executives

Concentra Merger Sub, Inc.	10 percent owner	4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Concentra Biosciences, Llc	10 percent owner	4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Richard /ca/ Murray	director, officer: CEO and President	22643 WOODRIDGE CT, CUPERTINO CA 95014
Kevin C Tang	10 percent owner	4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Tang Capital Partners Lp	10 percent owner	4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Tang Capital Management Llc	10 percent owner	4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Hugh M Cole	officer: Chief Business Officer	C/O ARIAD PHARMACEUTICALS, INC, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Elizabeth Trehu	officer: Chief Medical Officer	C/O JOUNCE THERAPEUTICS, INC., 1030 MASSACHUSETTS AVENUE, CAMBRIDGE MA 02138
Kimberlee C Drapkin	officer: CFO and Treasurer	PREDIX PHARMACEUTICALS HOLDINGS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421
Third Rock Ventures Iii, L.p.	10 percent owner	29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
Jigar Raythatha	director	C/O JOUNCE THERAPEUTICS, INC., 780 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Third Rock Ventures Ii, L.p.	10 percent owner	29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
John Duncan Higgons	director	C/O AGIOS PHARMACEUTICALS, INC., 38 SIDNEY STREET, 2ND FLOOR, CAMBRIDGE MA 02139
Luisa Salter-cid	director	C/O GOSSAMER BIO, INC., 3013 SCIENCE PARK ROAD, SUITE 200, SAN DIEGO CA 92121
Gilead Sciences Inc	10 percent owner	333 LAKESIDE DR, FOSTER CITY CA 94404